{
  "source": "PA-Notification-CNS-Lumryz-Xyrem-Xywav.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2023 P 1118-12\nProgram Prior Authorization/Notification\nMedication Lumryz™ (sodium oxybate), sodium oxybate [Xyrem authorized\ngeneric (manufactured by Amneal)]*, sodium oxybate [Xyrem\nauthorized generic (manufactured by Hikma)], Xyrem®* (sodium\noxybate), Xywav™ (calcium, magnesium, potassium, and sodium\noxybates)\nP&T Approval Date 8/2009, 5/11/2010, 1/2011, 1/2012, 2/2013, 8/2013, 8/2014, 8/2015,\n7/2016, 7/2017, 7/2018, 8/2019, 8/2020, 12/2020, 11/2021, 11/2022,\n11/2023\nEffective Date 2/1/2024\n1. Background:\nLumryz, Xyrem (sodium oxybate) and Xywav are central nervous system depressants indicated for\nthe treatment of excessive daytime sleepiness (EDS) or cataplexy in patients with narcolepsy. Xyway\nis also indicated for idiopathic hypersomnia (IH) in adults.\nLumryz, Xyrem and Xywav are classified as a Schedule III controlled substance by Federal law. The\nactive ingredient, sodium oxybate or gamma-hydroxybutyrate (GHB), is listed in the most restrictive\nschedule of the Controlled Substances Act (Schedule I). Thus, non-medical uses are classified under\nSchedule I.\nLumryz, Xyrem and Xywav are available only through a REMS program with restricted distribution.\nThe REMS Program provides educational materials to the prescriber and the patient explaining the\nrisks and proper use of Lumryz, Xyrem and Xywav, and the required prescription form. Once it is\ndocumented that the patient has read and/or understood the materials, the drug will be shipped to the\npatient. The REMS Program also recommends patient follow-up every 3 months. Physicians are\nexpected to report all serious adverse events to the manufacturer.\nMembers will be required to meet the coverage criteria below.\n2. Coverage Criteriaa:\n© 2023 UnitedHealthcare Services, Inc.\n1\nA. Narcolepsy with Cataplexy (i.e., Narcolepsy Type 1)\n1. Initial Authorization\na. Lumryz, sodium oxybate [Xyrem authorized generic (manufactured by Amneal)]*,\nsodium oxybate [Xy",
    "care Services, Inc.\n1\nA. Narcolepsy with Cataplexy (i.e., Narcolepsy Type 1)\n1. Initial Authorization\na. Lumryz, sodium oxybate [Xyrem authorized generic (manufactured by Amneal)]*,\nsodium oxybate [Xyrem authorized generic (manufactured by Hikma)], Xyrem* or\nXywav will be approved based on all of the following criteria:\n(1) Diagnosis of narcolepsy with cataplexy (i.e., Narcolepsy Type 1) as confirmed by sleep\nstudy (unless the prescriber provides justification confirming that a sleep study would not\nbe feasible) 2\n–AND–\n(2) Symptoms of excessive daytime sleepiness (including but not limited to daily periods of\nirrepressible need to sleep or daytime lapses into sleep) are present.\n-AND-\n(3) Cataplexy is present\nAuthorization will be issued for 6 months.\n2. Reauthorization\na. The requested medication will be approved for continuation of therapy based on one of the\nfollowing criteria:\n(1) Reduction in frequency of cataplexy attacks associated with therapy\n–OR–\n(2) Reduction in symptoms of excessive daytime sleepiness associated with therapy\nAuthorization will be issued for 12 months.\nB. Narcolepsy without Cataplexy (i.e., Narcolepsy Type 2)\n1. Initial Authorization\na. Lumryz, sodium oxybate [Xyrem authorized generic (manufactured by Amneal)]*,\nsodium oxybate [Xyrem authorized generic (manufactured by Hikma)], Xyrem* or\nXywav will be approved based on all of the following criteria:\n(1) Diagnosis of narcolepsy without cataplexy (i.e., Narcolepsy Type 2) as confirmed by\nsleep study (unless the prescriber provides justification confirming that a sleep study\nwould not be feasible) 2\n© 2023 UnitedHealthcare Services, Inc.\n2\n–AND–\n(2) Symptoms of excessive daytime sleepiness (including but not limited to daily periods of\nirrepressible need to sleep or daytime lapses into sleep) are present.\n–AND–\n(3) Cataplexy is absent\nAuthorization will be issued for 6 months.\n2. Reauthorization\na. The requested medication will be approved for continuation of therapy based on the\nfollowing ",
    "re present.\n–AND–\n(3) Cataplexy is absent\nAuthorization will be issued for 6 months.\n2. Reauthorization\na. The requested medication will be approved for continuation of therapy based on the\nfollowing criterion:\n(1) Reduction in symptoms of excessive daytime sleepiness associated with therapy\nAuthorization will be issued for 12 months.\nC. Idiopathic Hypersomnia\n1. Initial Authorization\na. Xywav will be approved based both of the following criteria:\n(1) Diagnosis of idiopathic hypersomnia\n–AND–\n(2) Symptoms of excessive daytime sleepiness (including but not limited to daily periods of\nirrepressible need to sleep or daytime lapses into sleep) are present.\nAuthorization will be issued for 6 months.\n2. Reauthorization\na. Xywav will be approved for continuation of therapy based on the following criterion:\n(1) Reduction in symptoms of excessive daytime sleepiness associated with therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management programs\nmay apply.\n*Sodium oxybate [Xyrem authorized generic (manufactured by Amneal)] and brand Xyrem are typically\nexcluded from coverage.\n© 2023 UnitedHealthcare Services, Inc.\n3\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits and/or Medical Necessity may be in place.\n4. References:\n1. Xyrem [package insert]. Palo Alto, CA: Jazz Pharmaceuticals, Inc; April 2023.\n2. American Academy of Sleep Medicine. International Classification of Sleep Disorders:\nDiagnostic and Coding Manual. 3rd ed. Darien, IL: American Academy of Sleep Medicine; 2014.\n3. Morgenthaler TI1, Kapur VK, Brown T, et",
    " Sleep Medicine. International Classification of Sleep Disorders:\nDiagnostic and Coding Manual. 3rd ed. Darien, IL: American Academy of Sleep Medicine; 2014.\n3. Morgenthaler TI1, Kapur VK, Brown T, et al. Practice parameters for the treatment of narcolepsy\nand other hypersomnias of central origin. Sleep. 2007 Dec;30(12):1705-11.\n4. Wise MS1, Arand DL, Auger RR, et al. Treatment of narcolepsy and other hypersomnias of\ncentral origin. Sleep. 2007 Dec;30(12):1712-27.\n5. The Xyrem® International Study Group. A Double-Blind, Placebo-Controlled Study\nDemonstrates Sodium Oxybate Is Effective for the Treatment of Excessive Daytime Sleepiness in\nNarcolepsy. J Clin Sleep Med. 2005 Oct 15;1(4):391-7.\n6. Xywav [package insert]. Palo Alto, CA: Jazz Pharmaceuticals, Inc; April 2023.\n7. Lumryz [package insert]. Chesterfield, MO: Avadel CNS Pharmaceuticals, LLC; May 2023.\n8. Sodium Oxybate [package insert]. Bridgewater, NJ: Amneal Pharmaceuticals NY LLC; April\n2023.\n9. Sodium Oxybate [package insert]. Berkeley Heights, NJ: Hikma Pharmaceuticals USA Inc.;\nApril 2023.\nProgram Prior Authorization/Notification - Sodium oxybates\nChange Control\n8/2013 Reformatted initial authorization criteria language to ‘diagnosis of\nnarcolepsy as confirmed by sleep study.’ Updated formatting.\n8/2014 Annual review with no changes to Coverage Criteria. Updated\nBackground and References.\n8/2015 Annual review. Created separate criteria for Narcolepsy with and\nwithout Cataplexy. Increased initial authorization to 6 months.\nUpdated references.\n7/2016 Annual review with no changes to coverage criteria. Updated\nbackground and references.\n7/2017 Annual review with no changes to coverage criteria. Updated\nreferences.\n7/2018 Annual review with no changes to coverage criteria. Updated\nreferences.\n8/2019 Annual review with no changes to coverage criteria. Updated\nreferences.\n8/2020 Annual review with no changes to coverage criteria. Updated\nbackground.\n© 2023 UnitedHealthcare Services, Inc.\n4\n12/2020 Added Xywav t",
    " with no changes to coverage criteria. Updated\nreferences.\n8/2020 Annual review with no changes to coverage criteria. Updated\nbackground.\n© 2023 UnitedHealthcare Services, Inc.\n4\n12/2020 Added Xywav to criteria.\n11/2021 Added criteria for idiopathic hypersomnia for Xywav due to new\nlabeling.\n11/2022 Annual review. Added state mandate footnote. Updated references.\n11/2023 Added Lumryz to criteria. Noted sodium oxybate (manufactured by\nAmneal) and brand Xyrem are typically excluded.\n© 2023 UnitedHealthcare Services, Inc.\n5"
  ]
}